Varubi® (rolapitant) injectable emulsion – New formulation approval
October 25, 2017 – Tesaro announced the FDA approval of Varubi (rolapitant) injectable emulsion indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.
Top